Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Each participant will have 2 treatment periods, separated by a washout of at least 7 days. Participants will be randomized 1:1 to receive VMD-3866 gel in one period, and placebo gel in the other. Before the start of each treatment period, participants will have a Run-in period lasting 7 days, during which they will record NPRS scores each morning in a trial diary. Participants will continue to…”In the company’s words, NCT07072468 on ClinicalTrials.gov
- Tested for
- Chemotherapy-induced Peripheral Neuropathy, Chemotherapy-induced Neuropathic Pain, CIPN - Chemotherapy-Induced Peripheral Neuropathy, Peripheral Neuropathic Pain, Peripheral Nerve Injuries, Pain, Nerve, Pain, Chronic, Pain, Neuropathic and 9 more
- Main trialPhase 2
- “Peripheral neuropathy is a disorder caused by damage to the peripheral nerves. Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of certain chemotherapy drugs, such as platinum-based compounds, taxanes, and vinca alkaloids, which can damage nerve fibres by disrupting their structure and function. At present, relief of neuropathic pain in CIPN is limited, and existing therapies providing only modest and variable efficacy across patients. This is a study of VMD-3866 gel (the study medicine which is non-opioid, non-NSAID), an experimental new topical medicine for…”In the company’s words, NCT07072468 on ClinicalTrials.gov
Other drugs for Chemotherapy-induced Peripheral Neuropathy
- NipocalimabJohnson & Johnson (Janssen) · Phase 2/3
- NTX-001Neuraptive Therapeutics Inc. · Phase 3
- TanruprubartAnnexon, Inc. · Phase 3
- Pregabalin XRBrainfarma Industria Química e Farmacêutica S/A · Phase 3
- RiliprubartSanofi · Phase 3
- NTLA-2001Intellia Therapeutics · Phase 3
Coming up1
- 30 Jun 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 Jun 2027 | Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026